Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue
+14.0%
EPS
−277.9%
Free cash flow
−233.0%
Total debt
−10.5%

Quarter to September 2026, against a year earlier

119.22 1.21 +1.03%
Market cap
$24.1B
P/E
56.8×
Fwd P/E
55.6×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a

Incyte Corporation 10-Q filed Oct 28, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 4:03 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 29, 2025: 17 added · 95 removed · 74 modified; 12 with only figures updated

  1. Modified · Forward-Looking Statements

    This report contains forward-looking statements that involve risks and uncertainties. These statements relate to future periods, future events or our future operating or financial plans or performance. Often, these statements include the words “believe,” “expect,” “target,” “anticipate,” “intend,” “plan,” “seek,” “estimate,” “potential,” or words of similar meaning, or future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” or “may,” or the negative of these terms, and other similar expressions. These forward-looking statements include, among other things, statements as to: